Vedolizumab was safe and showed superiority over infliximab as first-line biologic therapy in the management of patients with UC.

Hidradenitis suppurativa is more common among patients with Crohn disease (CD) than ulcerative colitis (UC), yet bowel obstruction affects both CD and UC.

Patients with inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) show promising outcomes when receiving advanced therapies following liver transplantation, according to study ...